Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

Drug (Brand / Generic)

MAVYRET™ (glecaprevir/pibrentasvir)

Developer

AbbVie

Therapy Class

Pan-genotypic hepatitis C therapy

Current Indication

Chronic hepatitis C virus genotypes one to six

Market Sector

Virology

Development Status

Approved in the US
Expand

Go Top